Conmed Gains Bard Endoscopy Line For $80 Mil., Bolstering GI Therapy Biz
This article was originally published in The Gray Sheet
Executive Summary
Conmed's purchase of Bard endoscopy technology will allow the firm to enhance its existing electrosurgery offerings with an expanded gastroenterology product range
You may also be interested in...
Mid-Sized Bard Delivers Solid Growth In Device Landscape Of Giants, Infants
Bard aims to rely on execution in niche areas where it can comfortably sustain market leadership to deliver sustainable double-digit revenue growth, according to President & CEO Tim Ring
Mid-Sized Bard Delivers Solid Growth In Device Landscape Of Giants, Infants
Bard aims to rely on execution in niche areas where it can comfortably sustain market leadership to deliver sustainable double-digit revenue growth, according to President & CEO Tim Ring
Third Quarter 2004 Earnings In Brief
Epic growth proportions?: St. Jude Medical expects ICD sales of $570 mil.-$580 mil. in 2004. Reporting on the first full quarter with Epic HF and Atlas + HF CRT defibrillators on the market, the firm notes total ICD sales of $157 mil. in Q3, a 57% climb over the 2003 period. During the quarter, St. Jude extended its atrial fibrillation therapy portfolio, acquiring Irvine Medical and entering a purchase deal with Endocardial Solutions (1"The Gray Sheet" Sept. 27, 2004, p. 9). Earnings rose from $84 mil. in Q3 2003 to $91 mil. in Q3 2004, based on $578 mil. in sales, which represented 22% growth over last year. St. Jude took a special charge of $35 mil. for discontinuing Symmetry bypass aortic connectors...